NCT03262935: A trial that was reported late by Byondis B.V.
This trial has reported, although it was 456 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03262935 |
|---|---|
| Title | A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 15, 2017 |
| Completion date | March 31, 2021 |
| Required reporting date | March 31, 2022, midnight |
| Actual reporting date | June 30, 2023 |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | 456 |